Skip to content
Dx

ICD-10-CM 2027 diagnosis code

T65.843DToxic effect of xylazine, assault, subsequent encounter

✓ Billable / specificPOA exemptRequires 7th character

T65.843D is a valid, billable ICD-10-CM code for toxic effect of xylazine, assault, subsequent encounter. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2026 (effective October 1, 2025). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About T65.843D

T65.843D is the ICD-10-CM diagnosis code for toxic effect of xylazine, assault, subsequent encounter. It belongs to category T65 (toxic effect of other and unspecified substances), block T51-T65 (toxic effects of substances chiefly nonmedicinal as to source) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

The 7th character "D" means subsequent encounter: use it for encounters after active treatment, while the patient is healing or recovering.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 949 (Aftercare with CC/MCC, relative weight 1.123) and DRG 950 (Aftercare without CC/MCC, relative weight 0.7664), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2026, effective October 1, 2025.

7th character

Dsubsequent encounter

Other encounter types for T65.843:

Notes that apply from higher levels

Instructions written at a parent level also apply to T65.843D.

› From T65.84 Toxic effect of xylazine
Use additional code
  • code(s) for all associated manifestations, such as:
  • cellulitis and acute lymphangitis (L03.-)
  • cutaneous abscess, furuncle and carbuncle (L02.-)
  • non-pressure chronic ulcer of lower limb, not elsewhere classified (L97.-)
  • non-pressure chronic ulcer of skin, not elsewhere classified (L98.4-)

Broader instructions also apply from T51-T65 Toxic effects of substances chiefly nonmedicinal as to source and Chapter 19: Injury, poisoning and certain other consequences of external causes.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

MDC 23 · Factors Influencing Health Status and Other Contacts with Health Services

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2026 (effective 10/1/2025): Added
  • No changes since FY2026.

Common questions about T65.843D

Is T65.843D billable?

Yes. T65.843D is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

What does the "D" at the end of T65.843D mean?

It is the 7th character for subsequent encounter. Per the official guidelines, use it for encounters after active treatment, while the patient is healing or recovering.

Can T65.843D be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict T65.843D as a principal diagnosis.

Is T65.843D a CC or MCC?

No. T65.843D is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does T65.843D group to?

T65.843D is used in the MS-DRG v44.0 logic for MS-DRG 949 (Aftercare with CC/MCC) and MS-DRG 950 (Aftercare without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.